144 related articles for article (PubMed ID: 35098660)
41. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
[TBL] [Abstract][Full Text] [Related]
42. Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors.
Kulikowska de Nałęcz A; Ciszak L; Usnarska-Zubkiewicz L; Pawlak E; Frydecka I; Szmyrka M; Kosmaczewska A
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982802
[TBL] [Abstract][Full Text] [Related]
43. A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.
Schuhmacher B; Rengstl B; Döring C; Bein J; Newrzela S; Brunnberg U; Kvasnicka HM; Vornanen M; Küppers R; Hansmann ML; Hartmann S
Oncotarget; 2016 Nov; 7(44):72197-72210. PubMed ID: 27708232
[TBL] [Abstract][Full Text] [Related]
44. Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives.
Lin N; Song Y; Zhu J
Chin J Cancer Res; 2020 Jun; 32(3):303-318. PubMed ID: 32694896
[TBL] [Abstract][Full Text] [Related]
45. The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma.
Krittikarux S; Wudhikarn K; Tangnuntachai N; Assanasen T; Sukswai N; Asawapanumas T; Chanswangphuwana C
Leuk Lymphoma; 2020 Dec; 61(14):3395-3403. PubMed ID: 32820659
[TBL] [Abstract][Full Text] [Related]
46. Relationship between the absolute lymphocyte count/absolute monocyte count ratio, soluble interleukin 2 receptor level, serum programmed cell death 1 level, and the prognosis of patients with diffuse large B-cell lymphoma.
Li C; Li W; Xu G; You M; Wu W; Kuang L
Ann Palliat Med; 2021 Oct; 10(10):10938-10945. PubMed ID: 34763456
[TBL] [Abstract][Full Text] [Related]
47. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
[TBL] [Abstract][Full Text] [Related]
48. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma.
Tobin JWD; Bednarska K; Campbell A; Keane C
Cells; 2021 May; 10(5):. PubMed ID: 34068762
[TBL] [Abstract][Full Text] [Related]
49. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.
Keane C; Vari F; Hertzberg M; Cao KA; Green MR; Han E; Seymour JF; Hicks RJ; Gill D; Crooks P; Gould C; Jones K; Griffiths LR; Talaulikar D; Jain S; Tobin J; Gandhi MK
Lancet Haematol; 2015 Oct; 2(10):e445-55. PubMed ID: 26686046
[TBL] [Abstract][Full Text] [Related]
50. The immune checkpoint expression in the tumor immune microenvironment of DLBCL: Clinicopathologic features and prognosis.
Ma J; Pang X; Li J; Zhang W; Cui W
Front Oncol; 2022; 12():1069378. PubMed ID: 36561512
[TBL] [Abstract][Full Text] [Related]
51. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
52. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
53. Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma.
Ballhausen A; Ben Hamza A; Welters C; Dietze K; Bullinger L; Rahn HP; Hartmann S; Hansmann ML; Hansmann L
Cancer Immunol Immunother; 2023 Feb; 72(2):515-521. PubMed ID: 35947165
[TBL] [Abstract][Full Text] [Related]
54. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
55. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
[TBL] [Abstract][Full Text] [Related]
56. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma].
Maruyama D
Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053
[TBL] [Abstract][Full Text] [Related]
57. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma without mediastinal disease: mimicking nodular sclerosis classical Hodgkin lymphoma.
Iwaki N; Sato Y; Kurokawa T; Maeda Y; Ohno K; Takeuchi M; Takata K; Orita Y; Nakao S; Yoshino T
Med Mol Morphol; 2013 Sep; 46(3):172-6. PubMed ID: 23512149
[TBL] [Abstract][Full Text] [Related]
58. The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.
Ozturk V; Yikilmaz AS; Kilicarslan A; Bakanay SM; Akinci S; Dilek İ
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e375-e381. PubMed ID: 32295735
[TBL] [Abstract][Full Text] [Related]
59. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.
Vardhana S; Cicero K; Velez MJ; Moskowitz CH
Oncologist; 2019 Jan; 24(1):86-95. PubMed ID: 30082490
[TBL] [Abstract][Full Text] [Related]
60. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients.
Karihtala K; Leivonen SK; Karjalainen-Lindsberg ML; Chan FC; Steidl C; Pellinen T; Leppä S
Blood Adv; 2022 Mar; 6(6):1919-1931. PubMed ID: 34941990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]